Evidence map›Paper›PMID 34391439›Full record

ArticleCost effectiveness and resource allocation : C/E2021

Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment.

Young-Sil Lee, HyunChul Youn, Hyun-Ghang Jeong, Tae-Jin Lee, Ji Won Han, Joon Hyuk Park, Ki Woong Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Thalamic nuclei insights into Alzheimer's disease.bioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Review
  9. Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction.Applications of medical artificial intelligence. AMAI (Workshop) (4th : 2024 : Taejon-si, Korea) · 2026
    Article
  10. Review
  11. Review
  12. Nationwide Survey on the Awareness of Mild Cognitive Impairment.Dementia and neurocognitive disorders · 2025
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Young-Sil Lee *Department of Public Health Science, Graduate School of Public Health, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
HyunChul Youn *Department of Psychiatry, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon, 14584, Republic of Korea.
Hyun-Ghang JeongDepartment of Psychiatry, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-Ro, Guro-gu, Seoul, 08308, Republic of Korea. jeonghg@korea.ac.kr.ORCID http://orcid.org/0000-0002-0318-5069
Tae-Jin LeeDepartment of Public Health Science, Graduate School of Public Health, Seoul National University, 1, Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. tjlee@snu.ac.kr.
Ji Won HanDepartment of Neuropsychiatry, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.
Joon Hyuk ParkDepartment of Psychiatry, Jeju National University School of Medicine, Jeju National University Hospital, Aran 13 gil, Jeju-si, Jeju, 63241, Republic of Korea.
Ki Woong KimDepartment of Neuropsychiatry, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.

Funding

Ministry of Health and Welfare HC15C1509Ministry of Health and Welfare HI09C1379 (A092077)
6 · The paper itself

Abstract

backgroundAmyloid positron emission tomography (PET) makes it possible to diagnose Alzheimer's disease (AD) in its prodromal phase including mild cognitive impairment (MCI). This study evaluated the cost-effectiveness of including amyloid-PET for assessing individuals with MCI.

methodsThe target population was 60-year-old patients who were diagnosed with MCI. We constructed a Markov model for the natural history of AD with the amyloid positivity (AP). Because amyloid-PET can detect the AP MCI state, AD detection can be made faster by reducing the follow-up interval for a high-risk group. The health outcomes were evaluated in quality-adjusted life years (QALYs) and the final results of cost-effectiveness analysis were presented in the form of the Incremental Cost-Effectiveness Ratio (ICER). To handle parameter uncertainties, one-way sensitivity analyses for various variables were performed.

resultsOur model showed that amyloid-PET increased QALYs by 0.003 in individuals with MCI. The estimated additional costs for adopting amyloid-PET amounted to a total of 1250 USD per patient when compared with the cost when amyloid-PET is not adopted. The ICER was 3,71,545 USD per QALY. According to the sensitivity analyses, treatment effect of Donepezil and virtual intervention effect in MCI state were the most influential factors.

conclusionsIn our model, using amyloid-PET at the MCI stage was not cost-effective. Future advances in management of cognitive impairment would enhance QALYs, and consequently improve cost-effectiveness.

Indexed as

Alzheimer’s diseaseAmyloidCost-effectivenessEarly diagnosisMild cognitive impairment

Identifiers

PMID34391439
PMCPMC8364075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.